Playback speed
10 seconds
Early Returns on FLAURA Trial: Osimertinib as First Line Agent in EGFR Mut-Pos. NSCLC?
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
14 views
November 2, 2018
Dr. Jack West discusses the implications of a positive FLAURA trial, which revealed a significant ...
read more ↘ improvement in progression-free survival for first line osimertinib over gefitinib or erlotinib in patients with EGFR mutation-positive advanced NSCLC.
↖ read less
read more ↘ improvement in progression-free survival for first line osimertinib over gefitinib or erlotinib in patients with EGFR mutation-positive advanced NSCLC.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung